Weekly semaglutide: 14.9% weight loss in the STEP 1 trial

In adults with overweight or obesity without diabetes, weight loss was sustained and clinically relevant versus placebo.

STEP 1 was a phase 3, randomised, double-blind trial in adults with overweight or obesity without diabetes. Participants received once-weekly semaglutide or placebo, alongside lifestyle intervention, for 68 weeks.

The semaglutide group lost an average of 14.9% of body weight and 86% reached at least 5% weight loss. The most frequent adverse events were gastrointestinal. The study was published in the New England Journal of Medicine.

In three points

Phase 3, double-blind, placebo-controlled human trial
Mean weight loss of 14.9% at 68 weeks
86% of participants lost at least 5% of body weight

Compounds mentioned

Semaglutide

Original source: Once-Weekly Semaglutide in Adults with Overweight or Obesity
PubMed · New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.